Evaluation of Inofolic treatment in women with polycystic ovary syndrome (PCOs)

The effects of Inofolic treatment on genomic profile of cumulus cells in PCOs women through ART cycles

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016122226668N2

Enrollment

Registered

2017-03-22

Start date

2017-01-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovarian Syndrome (PCOs). Other specified disorders of kidney and ureter

Interventions

Inofolic treatment.

Treatment - Drugs

Inofolic treatment

Eligibility

Sex/Gender

Female

Age

25 Years to 35 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: The mean age of the women taking part in this study was 26±3.87 (range 18-35); Polycystic Ovary Syndrome; hyperandrogenism; oligomenoreh. Exclusion criteria: any pathological uterine disorder; endometriosis; coagulation disorders; oral contraception or an intrauterine device used during three previous months.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Increase the number of mature oocytes and oocyte quality in women with polycystic ovary syndrome after inofolic treatment. Timepoint: Two months after starting the inofolic. Method of measurement: The assesment of the oocytes using microscope.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Fatemehsadat Amjadi

Iran University of Medical Sciences

ivco@iums.ac.ir; amjadi.bh@gmail.com+98 21 8601 8542

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026